Literature DB >> 7575698

Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus.

H Chabre1, Z Amoura, J C Piette, P Godeau, J F Bach, S Koutouzov.   

Abstract

OBJECTIVE: To assess whether nucleosome-restricted antibodies, i.e., antibodies that react with the whole nucleosome particle but not with its individual components (double-stranded DNA [dsDNA] and histones), are present in the sera of patients with systemic lupus erythematosus (SLE).
METHODS: Antibodies were detected by enzyme-linked immunosorbent assay using purified nucleosomes, dsDNA, or histones. These tests were applied to the sera of 40 patients with SLE. Protein G-purified IgGs of representative sera were sequentially adsorbed on dsDNA- and histone-conjugated solid-phase supports and further assayed for their nucleosome, dsDNA, and histone reactivities.
RESULTS: Of the 40 sera tested, 16 displayed anti-dsDNA and/or antihistone antibody activity, which was always associated with significant antinucleosome reactivity. In addition, 3 sera showed antinucleosome activity that was not associated with concomitant anti-dsDNA or antihistone activity. The presence of true nucleosome-restricted antibodies was demonstrated, after solid-phase adsorption, in representative SLE sera that showed anti-dsDNA or antihistone antibody activity, and also in sera that did not show these activities.
CONCLUSION: Our results provide evidence for the presence of nucleosome-restricted antibodies in patients with lupus. These nucleosome-restricted antibodies, along with anti-dsDNA and antihistone antibodies, appear to belong to a broad set of antinuclear antibodies, the antinucleosome family.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575698     DOI: 10.1002/art.1780381015

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

Review 1.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  T cells of lupus and molecular targets for immunotherapy.

Authors:  S K Datta; A Kaliyaperumal; A Desai-Mehta
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

3.  Structural models of antibody variable fragments: a method for investigating binding mechanisms.

Authors:  S Petit; F Brard; G Coquerel; G Perez; F Tron
Journal:  J Comput Aided Mol Des       Date:  1998-03       Impact factor: 3.686

4.  Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus.

Authors:  A Kretz-Rommel; S R Duncan; R L Rubin
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

5.  Anti-subnucleosome reactivities in systemic lupus erythematosus (SLE) patients and their first-degree relatives.

Authors:  C Mohan; F Liu; C Xie; R C Williams
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

6.  Major peptide autoepitopes for nucleosome-specific T cells of human lupus.

Authors:  L Lu; A Kaliyaperumal; D T Boumpas; S K Datta
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

7.  Biomarkers in systemic lupus erythematosus: challenges and prospects for the future.

Authors:  Chau-Ching Liu; Amy H Kao; Susan Manzi; Joseph M Ahearn
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

8.  Anti-chromatin and anti-histone antibodies in Egyptian patients with systemic lupus erythematosus.

Authors:  Adel A Shabana; Atef E El-Ghawet; Shereen A Machaly; Ekbal M Abu Hashim; Basma A El-Kady; Reham Shaat
Journal:  Clin Rheumatol       Date:  2009-03-14       Impact factor: 2.980

9.  Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus.

Authors:  J B Lefkowith; M Kiehl; J Rubenstein; R DiValerio; K Bernstein; L Kahl; R L Rubin; M Gourley
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

10.  Isolation of anti-nucleosome antibodies from the plasma of lupus nephritis patients.

Authors:  R Suenaga; K Mitamura; N I Abdou
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.